<DOC>
	<DOCNO>NCT00003985</DOCNO>
	<brief_summary>RATIONALE : Biological therapy KRN7000 use different way stimulate immune system stop cancer cell grow . PURPOSE : Phase I trial study effectiveness KRN7000 treat patient solid tumor respond previous treatment .</brief_summary>
	<brief_title>KRN7000 Treating Patients With Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Determine safety profile maximum tolerate dose KRN7000 patient solid tumor . II . Assess biological immunological parameter would suggest optimal biologically active dose KRN7000 patient . III . Determine pharmacokinetics KRN7000 different dose level patient . IV . Measure antitumor activity patient treat regimen . OUTLINE : This dose escalation study . Patients receive KRN7000 slow intravenous injection day 1 , 8 , 15 . Treatment repeat every 28 day 6 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos KRN7000 maximum tolerate dose ( MTD ) determine . The MTD define dose least 2 6 patient experience dose limit toxicity . PROJECTED ACCRUAL : Approximately 40 patient accrue study within 18 month .</detailed_description>
	<mesh_term>KRN 7000</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically proven solid tumor refractory conventional treatment curative standard palliative treatment exist No brain involvement leptomeningeal disease PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG/WHO 02 Life expectancy : At least 3 month Hematopoietic : WBC least 4,000/mm3 Platelet count least 100,000/mm3 Lymphocyte count least 600/mm3 Hepatic : Bilirubin le 1.5 mg/dL AST ALT great 2.5 time upper limit normal No liver cirrhosis Hepatitis B surface antigen negative Renal : Creatinine great 1.4 mg/dL OR Creatinine clearance least 60 mL/min Cardiovascular : No New York Heart Association class III IV heart disease Immunologic : No immunodeficiency No autoimmune disease Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No active infection No nonmalignant disease incompatible study No prior alcoholism , drug addiction , psychotic disorder unless suitable adequate follow No cerebroside metabolite abnormality ( e.g. , Gaucher 's disease ) HIV negative PRIOR CONCURRENT THERAPY : Biologic therapy : At least 3 month since prior immunotherapy No concurrent cytokine Chemotherapy : At least 4 week since prior chemotherapy ( 6 week nitrosoureas , mitomycin , high dose chemotherapy ) Endocrine therapy : Not specify Radiotherapy : At least 4 week since prior radiotherapy ( 6 week extensive radiotherapy ) No concurrent radiotherapy Surgery : Not specify Other : No concurrent investigational antitumor drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>